Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Montalban

Showing results (1-10 of 559) with videos related to

Pageof 56
Sort By:
Journal of the Neurological Sciences|December 31, 2011
Review of methodological issues of clinical trials in multiple sclerosisXavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosisXavier Montalban
International MS Journal|December 9, 2004
Diagnosis and treatment of MS in Latin America. MS Forum Interactive Symposium at the LACTRIMS Congress, 27 August 2004, Iguazu Falls, BrazilXavier Montalban
Journal of the Neurological Sciences|January 29, 2010
Early treatment: PreCISe-ly what the patient needsXavier Montalban
Journal of Neurology|September 21, 2004
The pros and cons of early treatment of relapsing forms of multiple sclerosisXavier Montalban
Current Opinion in Neurology|May 14, 2005
Primary progressive multiple sclerosisXavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2013
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosisCarmen Tur, Xavier Montalban
The Lancet. Neurology|December 17, 2013
Body fluid biomarkers in multiple sclerosisManuel Comabella, Xavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2014
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et alCarmen Tur, Xavier Montalban
Nature Reviews. Neurology|January 8, 2014
Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measuresXavier Montalban, Mar Tintoré
Pageof 56

Showing results (1-10 of 559) with videos related to

Sort By:
Pageof 56
Journal of the Neurological Sciences|December 31, 2011
Review of methodological issues of clinical trials in multiple sclerosisXavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2004
Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosisXavier Montalban
International MS Journal|December 9, 2004
Diagnosis and treatment of MS in Latin America. MS Forum Interactive Symposium at the LACTRIMS Congress, 27 August 2004, Iguazu Falls, BrazilXavier Montalban
Journal of the Neurological Sciences|January 29, 2010
Early treatment: PreCISe-ly what the patient needsXavier Montalban
Journal of Neurology|September 21, 2004
The pros and cons of early treatment of relapsing forms of multiple sclerosisXavier Montalban
Current Opinion in Neurology|May 14, 2005
Primary progressive multiple sclerosisXavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2013
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosisCarmen Tur, Xavier Montalban
The Lancet. Neurology|December 17, 2013
Body fluid biomarkers in multiple sclerosisManuel Comabella, Xavier Montalban
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2014
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et alCarmen Tur, Xavier Montalban
Nature Reviews. Neurology|January 8, 2014
Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measuresXavier Montalban, Mar Tintoré
Pageof 56